Soligenix Shares Rally On Positive Preclinical Data For COVID-19 Vaccine Candidate

Soligenix Inc (NASDAQ: SNGX) rises sharply in premarket trading after the publication of positive results from pre-clinical immunogenicity studies for the COVID-19 vaccine candidate, dubbed as CiVax.

  • The data demonstrated rapid-onset, neutralizing antibody and cell-mediated immunity using full-length Spike protein antigens.
  • This work will continue under a $1.5M Small Business Innovation Research (SBIR) grant awarded to Soligenix in December last year.
  • CiVax is Soligenix's heat-stable subunit vaccine candidate for the prevention of COVID-19 infection.
  • The following steps will include evaluating immunogenicity in a non-human primate model and assessing antibody coverage with key variants of the virus.
  • Price Action: SNGX shares gained 34.8% at $2.18 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!